作者
Francesca Ruffilli,Francesca Crisafulli,C. Nalli,A.C. Pozzi,Guerrino Voltarel,Carlo Garaffoni,Marcello Govoni,Alessandra Bortoluzzi,A. Tincani
摘要
Background: ACR and EULAR recently developed new classification criteria for antiphospholipid syndrome (APS) [1]. Several studies have evaluated the impact of these criteria on existing APS cohorts, demonstrating greater specificity but lower sensitivity compared to the previous Sydney criteria. However, there has been limited focus on specifically assessing the sensitivity of these criteria in populations where obstetric complications are the predominant manifestation of the disease. Objectives: This study aims to assess the sensitivity of the ACR/EULAR classification criteria in a cohort of patients with primary obstetric APS (OAPS), as diagnosed by experienced rheumatologists. As a secondary objective, we assessed the occurrence of new events during follow-up. Methods: A retrospective observational study was conducted on patients with OAPS, followed at two Italian centers between January 2006 and December 2023. Patients with secondary APS were excluded. Patients' records, including demographic data, clinical history, laboratory results, and clinical disease characteristics, were collected using a web-based database, along with information on the fulfillment of the Sydney and ACR/EULAR classification criteria. When available, data at 12 months after diagnosis were analyzed. The results were analyzed descriptively and reported as numbers and percentages (%) for categorical variables, and as mean values (SD) for continuous variables. Results: We enrolled 121 women diagnosed with OAPS (demographic and laboratory characteristics in Table 1). Twenty-six (22%) patients were classified as APS based on the ACR/EULAR criteria, compared to 91 (75%) who met the Sydney criteria. Patients who fulfilled the new classification criteria were younger (p=0.014) compared to those who did not meet these criteria, and they exhibited a significantly higher prevalence of triple aPL positivity (p = 0.001), indicative of a high-risk aPL profile. Early miscarriages were significantly underrepresented in the ACR/EULAR classification criteria group (23% vs 96%, p<0.001). In contrast, preterm births and severe placental disorders were more frequent in this group (75% vs 3%, p<0.001). Furthermore, venous thrombotic events and thrombocytopenia were significantly more frequent among the classifiable patients (p= 0.001). Serologically, these patients exhibited higher persistent LAC positivity (p = 0.010) and a greater frequency of high-titer IgG aPL positivity, and a lower frequency of moderate/high-titer IgM aPL positivity and medium-titer IgG aPL positivity (p = 0.002). The sensitivity of the ACR/EULAR criteria in our cohort was 20.4%, substantially lower compared to the Sydney criteria (77.8%). Among the 93 patients followed after diagnosis, 15% experienced at least one new obstetric event, with early miscarriages being the most common, followed by placental disorders and fetal deaths after 10 WG. No thrombotic events occurred during follow-up. One additional patient was classified as having APS according to the new criteria during this period. Patients with new obstetric events had higher rates of congenital thrombophilia (p = 0.004) and increased triple aPL positivity (p = 0.070) than those without new events. Notably, although no significant differences were found between patients classified and those not classified at baseline, a higher percentage of patients with new obstetric events met the Sydney criteria at baseline (79%), compared to a low percentage of patients classifiable according to the ACR/EULAR criteria (21%) (Figure 1). Conclusion: In our cohort, the ACR/EULAR classification criteria demonstrated low sensitivity, with over three-quarters of diagnosed OAPS patients not meeting the new criteria. This discrepancy is largely due to the limited weight assigned to recurrent fetal losses and isolated IgM antibody positivity. Patients who met the ACR/EULAR criteria appear to exhibit a more severe disease phenotype with an earlier onset. However, these criteria seem to exclude less severe but more common phenotypes observed in real-world populations, which still warrant physician attention. Additionally, the new criteria identify a smaller proportion of patients who develop new events during follow-up compared to the Sydney criteria. The new classification criteria have high specificity for selecting severe patients for research purposes. As previously stated, classification criteria should not be used as diagnostic criteria, particularly in the context of OAPS. REFERENCES: [1] Barbhaiya M et al. Arthritis Rheumatol. 2023 Oct;75(10):1687-1702. Figure 1Fulfillment of the ACR/EULAR classification criteria and the Sydney classification criteria at baseline among patients who developed new obstetric events within 12 months of follow-up. Table 1Demographic and laboratory characteristics.TotalN 1 = 121ACR/EULARN 1 = 26No ACR/EULARN 1 = 95P-valueCaucasian ethnicity102 (84%)21 (80.8%)81 (85.3%)0.6Age at diagnosis (yrs)35 (± 6)33 (± 4)35 (± 7)0.014BMI (kg/m 2 )24.7 (± 5.1)25.4 (± 5.6)24.5 (± 4.9)0.5Current smokers11 (9.1%)3 (11.5%)8 (8.4%)0.7Inherited thrombophilia43 (36%)7 (26.9%)36 (37.9%)0.3Arterial hypertension16 (13.2%)7 (26.9%)9 (9.5%)0.043Autoimmune thyroiditis17 (14%)2 (7.7%)15 (15.8%)0.4LAC28 (23.1%)13 (50%)15 (15.8%)<0.001IgG aCL51 (42.1%)17 (65.4%)34 (35.8%)0.007IgM aCL30 (24.8%)1 (3.8%)29 (30.5%)0.005IgG aβ2GPI52 (43%)16 (62.5%)36 (37.9%)0.031IgM aβ2GPI37 (30.6%)9 (34.6%)28 (29.5%)0.6Triple aPL positivity24 (19.8%)11 (42.3%)13 (13.7%)0.001C3 (mg/dl)121 (± 28)122 (± 37)120 (± 25)0.9C4 (md/dl)24 (± 8)24 (± 9)24 (± 8)> 0.9 1: N (%), Mean (± SD ) Abbreviations : aB2GPI: anti-B2glycoprotein I; aCL: anticardiolipin; aPL: antiphospholipid; BMI: body mass index; LAC: lupus anticoagulant. Acknowledgements: NIL . Disclosure of Interests: None declared . © The Authors 2025. This abstract is an open access article published in Annals of Rheumatic Diseases under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). Neither EULAR nor the publisher make any representation as to the accuracy of the content. The authors are solely responsible for the content in their abstract including accuracy of the facts, statements, results, conclusion, citing resources etc.